Novanta (NOVT) Q2 Revenue Rises 2.2%

Novanta (NOVT) reported Q2 2025 results, surpassing analyst expectations with GAAP revenue of $241.0 million (+2.2% YoY) and adjusted EPS of $0.76 (+4.1% YoY). However, free cash flow sharply declined 67.7% to $11.7 million and GAAP net income fell 67.4%, primarily due to significant acquisition-related costs, restructuring expenses, and increased inventory investments to mitigate global trade risks. Despite resilience in advanced surgery and robotics, organic revenue contracted 2.1%; the company is implementing a $20 million cost savings program and anticipates sequential improvement, though the business environment remains unpredictable.

Analysis

Novanta (NOVT) reported mixed Q2 2025 results, characterized by a top-line beat that masks significant underlying operational and profitability pressures. The company exceeded consensus estimates with GAAP revenue of $241.0 million, a 2.2% year-over-year increase, and non-GAAP adjusted EPS of $0.76, up 4.1%. However, this growth was not organic, as the company reported a 2.1% contraction in underlying organic revenue, indicating that recent M&A activity is the primary driver. More concerning were the sharp declines in profitability and cash generation; GAAP net income fell 67.4% and non-GAAP free cash flow plunged 67.7% to just $11.7 million. Management attributed these declines to $12.6 million in acquisition and restructuring costs, increased inventory purchases to de-risk the supply chain from global trade dynamics, and the timing of tax payments. Segment performance was bifurcated: the Automation Enabling Technologies segment grew 4.3%, while the larger Medical Solutions segment saw only slight growth, with strong demand in advanced surgery being offset by weakness in precision medicine due to NIH funding cuts and tariffs. While forward guidance for Q3 and the full year 2025 suggests sequential improvement, it is contingent on mitigating trade impacts, which could defer up to $35 million in revenue, and achieving a projected $20 million in annualized cost savings.

Key Decisions for Investors

• Investors should scrutinize the divergence between Novanta's acquisition-driven top-line growth and its contracting organic revenue of 2.1%, as this signals potential weakness in core end-markets.
• Monitor free cash flow generation in the upcoming quarters to validate management's explanation of temporary pressures versus a more systemic deterioration in operational efficiency.
• The successful integration of the Keonn acquisition and the execution of the $20 million cost-saving plan are critical catalysts to watch, as they are key to offsetting margin pressure from restructuring and ongoing trade-related disruptions.